secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-028369
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval
--------------------------------------------------------------------------------

- FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.
- DYNE-251 in DMD: registrational expansion cohort enrollment targeted Q1 2025; data expected late 2025.
- Cash and equivalents $642.3M at Dec 31, 2024; plus $140.6M from ATM in Q1 2025; runway into H2 2026.
- Q4 2024 net loss $89.5M ($0.88 per share) vs $66.6M (Q4 2023); R&D expenses $81.8M (Q4 2024).
- Potential U.S. accelerated approval submissions for DYNE-101 in H1 2026 and DYNE-251 in early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/0000950170-25-028369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/dyn-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-028369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer